Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy - PubMed

Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy

Matthew D Vesely et al. Ann N Y Acad Sci. 2013 May.

Abstract

Accumulated data from animal models and human cancer patients strongly support the concept that the immune system can identify and control nascent tumor cells in a process called cancer immunosurveillance. In addition, the immune system can also promote tumor progression through chronic inflammation, immunoselection of poorly immunogenic variants, and suppressing antitumor immunity. Together, the dual host-protective and tumor-promoting actions of immunity are referred to as cancer immunoediting. The current framework of cancer immunoediting is a dynamic process comprised of three distinct phases: elimination, equilibrium, and escape. Recently, we demonstrated that immunoselection by CD8(+) T cells of tumor variants lacking strong tumor-specific antigens represents one mechanism by which cancer cells escape tumor immunity and points toward the future of personalized cancer therapy.

Similar articles

• Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.

  Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD. Matsushita H, et al. Nature. 2012 Feb 8;482(7385):400-4. doi: 10.1038/nature10755. Nature. 2012. PMID: 22318521 Free PMC article.

• Cancer immunoediting: from immunosurveillance to tumor escape.

  Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Dunn GP, et al. Nat Immunol. 2002 Nov;3(11):991-8. doi: 10.1038/ni1102-991. Nat Immunol. 2002. PMID: 12407406 Review.

• Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.

  Kunimasa K, Goto T. Kunimasa K, et al. Int J Mol Sci. 2020 Jan 17;21(2):597. doi: 10.3390/ijms21020597. Int J Mol Sci. 2020. PMID: 31963413 Free PMC article. Review.

• Expression of tumour-specific antigens underlies cancer immunoediting.

  DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. DuPage M, et al. Nature. 2012 Feb 8;482(7385):405-9. doi: 10.1038/nature10803. Nature. 2012. PMID: 22318517 Free PMC article.

• The immunobiology of cancer immunosurveillance and immunoediting.

  Dunn GP, Old LJ, Schreiber RD. Dunn GP, et al. Immunity. 2004 Aug;21(2):137-48. doi: 10.1016/j.immuni.2004.07.017. Immunity. 2004. PMID: 15308095 Review.

Cited by

• Lipid Metabolism in Tumor-Associated Natural Killer Cells.

  Chen Y, Sui M. Chen Y, et al. Adv Exp Med Biol. 2021;1316:71-85. doi: 10.1007/978-981-33-6785-2_5. Adv Exp Med Biol. 2021. PMID: 33740244 Review.

• Mitigating non-genetic resistance to checkpoint inhibition based on multiple states of immune exhaustion.

  Kareva I, Gevertz JL. Kareva I, et al. NPJ Syst Biol Appl. 2024 Feb 9;10(1):14. doi: 10.1038/s41540-024-00336-6. NPJ Syst Biol Appl. 2024. PMID: 38336968 Free PMC article.

• Prognostic significance of preoperative peripheral blood neutrophil to lymphocyte ratio (NLR) in lung sarcomatoid carcinoma.

  Liu J, Li S, Liu H, Chen K, Chen R, Xiao Y, Zhang X, Chen J. Liu J, et al. Transl Cancer Res. 2019 Sep;8(5):1826-1833. doi: 10.21037/tcr.2019.08.35. Transl Cancer Res. 2019. PMID: 35116933 Free PMC article.

• Exploring the Potential Utility of Pet Dogs With Cancer for Studying Radiation-Induced Immunogenic Cell Death Strategies.

  Fan TM, Selting KA. Fan TM, et al. Front Oncol. 2019 Jan 15;8:680. doi: 10.3389/fonc.2018.00680. eCollection 2018. Front Oncol. 2019. PMID: 30697532 Free PMC article. Review.

• α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas.

  Dodagatta-Marri E, Meyer DS, Reeves MQ, Paniagua R, To MD, Binnewies M, Broz ML, Mori H, Wu D, Adoumie M, Del Rosario R, Li O, Buchmann T, Liang B, Malato J, Arce Vargus F, Sheppard D, Hann BC, Mirza A, Quezada SA, Rosenblum MD, Krummel MF, Balmain A, Akhurst RJ. Dodagatta-Marri E, et al. J Immunother Cancer. 2019 Mar 4;7(1):62. doi: 10.1186/s40425-018-0493-9. J Immunother Cancer. 2019. PMID: 30832732 Free PMC article.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal